Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Lennox Gastaut Syndrome 1Glioblastoma 1Epilepsy 1Epilepsies, Myoclonic 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Breast Neoplasms 1Arthralgia 1Anxiety Disorders 1

Interventions

Letrozole 4Anastrozole 3exemestane 2canakinumab 1Vitamin B 12 1Therapeutics 1Testosterone 1Tamoxifen 1Glucosamine 1Glucaric Acid 1Fatty Acids, Omega-3 1Chondroitin Sulfates 1Chondroitin 1Cholecalciferol 1Cannabidiol 1Calcium Gluconate 1Calcium Citrate 1Calcium Carbonate 1Calcium 1Aromatase Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Arthralgia × Cannabidiol × Clear all
NCT04754399 2025-05-09

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

University of Michigan Rogel Cancer Center

Phase 2 Completed
40 enrolled 10 charts
Breast

Breast Neoplasms, Arthralgia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡